

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP**

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

1. Name and Address of Reporting Person* <u>KAPLAN LESTER J PH D</u>			2. Issuer Name and Ticker or Trading Symbol <u>ACADIA PHARMACEUTICALS INC [ ACAD ]</u>			5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director 10% Owner Officer (give title below) Other (specify below)		
(Last)	(First)	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) <u>09/12/2013</u>			6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person		
<u>11085 TORREYANA ROAD #100</u>			4. If Amendment, Date of Original Filed (Month/Day/Year)					
(Street) <u>SAN DIEGO CA 92121</u>								
(City) (State) (Zip)								

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	09/12/2013		M		50	A	\$6.1	8,550	D	
Common Stock	09/12/2013		M		6,500	A	\$8.85	15,050	D	
Common Stock	09/12/2013		M		5,084	A	\$8.85	20,134	D	
Common Stock	09/12/2013		M		10,000	A	\$9.04	30,134	D	
Common Stock	09/12/2013		M		10,000	A	\$2.16	40,134	D	
Common Stock	09/12/2013		M		34,722	A	\$2.16	74,856	D	
Common Stock	09/12/2013		S <sup>(1)</sup>		66,356	D	\$22.9018 <sup>(2)</sup>	8,500	D	

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date						Title
Stock option (right to buy)	\$6.1	09/12/2013		M			50	(3)	06/13/2014	Common stock	50	\$0	4,450	D	
Stock option (right to buy)	\$8.85	09/12/2013		M			6,500	(4)	06/09/2015	Common stock	6,500	\$0	0	D	
Stock option (right to buy)	\$8.85	09/12/2013		M			5,084	(4)	06/09/2015	Common stock	5,084	\$0	0	D	
Stock option (right to buy)	\$9.04	09/12/2013		M			10,000	(5)	06/12/2016	Common stock	10,000	\$0	0	D	
Stock option (right to buy)	\$2.16	09/12/2013		M			10,000	(6)	06/11/2019	Common stock	10,000	\$0	0	D	
Stock option (right to buy)	\$2.16	09/12/2013		M			34,722	(6)	06/11/2019	Common stock	34,722	\$0	0	D	

**Explanation of Responses:**

- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in 2013.
- The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from \$22.64 to \$23.30 per share, inclusive. The reporting person undertakes to provide ACADIA Pharmaceuticals Inc., any security holder of ACADIA Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the foregoing range.
- 25% of the shares subject to the Stock Option vested and became exercisable at the end of each 3-month period following March 12, 2004.

4. 25% of the shares subject to the Stock Option vested and became exercisable at the end of each 3-month period following the date of grant of June 10, 2005.
5. 25% of the shares subject to the Stock Option vested and became exercisable at the end of each 3-month period following the date of grant of June 13, 2006.
6. 25% of the shares subject to the Stock Option vested and became exercisable at the end of each 3-month period following the date of grant of June 12, 2009.

/s/ Glenn F. Baity, Attorney-in-  
Fact 09/13/2013

\*\* Signature of Reporting Person      Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**

## POWER OF ATTORNEY

Know all by these presents, that the undersigned hereby authorizes **Uli Hacksell, Thomas H. Aasen, Glenn F. Baity** or **Kirk V. Crawford** to execute for and on behalf of the undersigned, in the undersigned's capacity as a director of **ACADIA Pharmaceuticals Inc.** (the "Company"), Forms 3, 4 and 5 and any Amendments thereto, and cause such form(s) to be filed with the Securities and Exchange Commission pursuant to Section 16(a) of the Securities Exchange Act of 1934, relating to the undersigned's beneficial ownership of securities in the Company. The undersigned hereby grants to such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or substitute or substitutes of such attorney-in-fact, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorney-in-fact, in serving in such capacity at the request of the undersigned, is not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4 and 5 with respect to the undersigned's holdings of, and transactions in, securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorney-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed this 5th day of September, 2013.

/s/ Lester Kaplan  
Lester Kaplan